Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas

References

• Okcu MF, Hicks J, Merchant TE et al. Nonrhabdomyosarcomatous soft tissue sarcomas. In: Principles and Practice of Pediatric Oncology (5th edition). Pizzo PA, Poplack DC (Eds). Lippincott, Williams & Wilkins, PA, USA, 1033–1073 (2006).
   Google Scholar
• Raney B, Parham D, Sommelet-Olive D et al. Summary of the International Symposium on childhood non-rhabdomyosarcoma soft-tissue sarcomas, Padua, Italy, 1994. Med. Pediatr. Oncol.26, 425–430 (1996).
   PubMedGoogle Scholar
• Rao BN. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin. Surg. Oncol.9, 524–531 (1993).
   PubMedGoogle Scholar
• McGrory JE, Pritchard DJ, Arndt CA et al. Nonrhabdomyosarcoma soft tissue sarcomas in children: the Mayo Clinic experience. Clin. Orthop.374, 247–258 (2000).
   Google Scholar
• Spunt SL, Poquette CA, Hurt YS et al. Prognostic factors for children and adolscents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital. J. Clin. Oncol.17, 3697–3705 (1999).
   PubMed Web of Science ®Google Scholar
• Spunt SL, Ashley Hill D, Motosue AM et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhaddomyosarcoma soft tissue sarcoma. J. Clin. Oncol.20, 3225–3235 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther.5(2), 307–318 (2005).
   PubMed Web of Science ®Google Scholar
• Walter AW, Shearer PD, Pappo AS et al. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Med. Pediatr. Oncol.30, 210–216 (1998).
   PubMedGoogle Scholar
• Pratt CB, Maurer HM, Gieser P et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group Study. Med. Pediatr. Oncol.30, 201–209 (1998).
   PubMedGoogle Scholar
• Pappo AS, Devidas M, Jenkins J et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J. Clin. Oncol.23, 4031–4038 (2005).
   PubMed Web of Science ®Google Scholar
• Nathan PC, Tsokos M, Long L et al. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr. Blood Cancer44, 449–454 (2005).
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol.11, 1269–1275 (1993).
   PubMed Web of Science ®Google Scholar
• Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol.11, 1276–1285 (1993).
   PubMed Web of Science ®Google Scholar
• Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of Phase II and pilot studies – dose-response and schedule dependence. J. Clin. Oncol.15, 2378–2384 (1997).
   PubMed Web of Science ®Google Scholar
• Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer73, 2506–2511 (1994).
   PubMed Web of Science ®Google Scholar
• Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer91, 1914–1926 (2001).
   PubMed Web of Science ®Google Scholar
• Trojani M, Contesso G, Coindre JM et al. Soft tissue sarcomas of adults: study of pathological prognostic variables and definitions of a histopathological grading system. Int. J. Cancer.33, 37–42 (1984).
   PubMed Web of Science ®Google Scholar
• Parham DM, Webber BL, Jenkins JJ et al. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod. Pathol.8, 705–710 (1995).
   PubMed Web of Science ®Google Scholar
• Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adults patients with soft tissue sarcoma. J. Clin. Oncol.15, 350–362 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Meazza C et al. Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol.23, 4021–4030 (2005).
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys.56, 1117–1127 (2003).
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. Lancet359, 2235–2241 (2002)
   PubMed Web of Science ®Google Scholar
• Cormier JN, Langstein HN, Pisters PW. Preoperative therapy for soft tissue sarcoma. Cancer Treat. Res.120, 43–63 (2004).
   PubMedGoogle Scholar
• Wolfson AH. Preoperative vs postoperative radiation therapy for extremity soft tissue sarcoma: controversy and present management. Curr. Opin Oncol.17(4), 357–360 (2005).
   PubMed Web of Science ®Google Scholar
• Rossi CR, Mocellin S, Pilati P et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol.12(5), 398–405 (2005).
   PubMed Web of Science ®Google Scholar
• Rossi CR, Deraco M, De Simone M et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer100(9), 1943–1950 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr. Oncol. Rep.8(4), 310–315 (2006).
   PubMedGoogle Scholar
• Bramwell V, Rouesse J, Steward W et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but no improvement in survival: a study on the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J. Clin. Oncol.12, 1137–1149 (1994).
   PubMed Web of Science ®Google Scholar
• Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J. Clin. Oncol.19, 1235–1237 (2001).
   PubMed Web of Science ®Google Scholar
• Demetri G.D. Highlights of sarcoma research. J. Clin. Oncol. Classic Papers Curr. Comments7, 681–684 (2002).
   Google Scholar
• Alvegard TA, Sigurdsson H, Mouridsen H et al. Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J. Clin. Oncol.7, 1504–1513 (1989)
   PubMed Web of Science ®Google Scholar
• Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol.13, 1537–1545 (1995).
   PubMed Web of Science ®Google Scholar
• No authors listed. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet350, 1647–1654 (1997).
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol.19, 1238–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Olmi P, Casali PG. Combined modalities approach for localised adult extremity soft-tissue sarcoma. Expert Rev. Anticancer Ther.7(8), 1135–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Woll PJ, Van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a Phase III trial. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10008).
   Google Scholar
• Cormier JN, Huang X, Xing Y et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J. Clin. Oncol.22, 4567–4574 (2004).
   PubMed Web of Science ®Google Scholar
• Pratt CB, Pappo AS, Gieser P et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J. Clin. Oncol.17, 1219–1226 (1999)
   PubMed Web of Science ®Google Scholar
• Ferrari A, Brecht IB, Koscielniak E et al. The role of adjuvant chemotherapy in surgically-resected adult-type soft tissue sarcomas of children and adolescents. Pediatr. Blood Cancer45, 128–134 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Collini P. The effectiveness of chemotherapy in non-rhabdomyosarcoma soft tissue sarcomas. Pediatr. Blood Cancer45(2), 226–227 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Miceli R, Casanova M et al. Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur. J. Cancer43, 2691–2697 (2007).
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Treuner J, Koscielniak E et al. Synovial sarcoma of childhood and adolescence: report of the German CWS-81 study. Cancer71, 3647–3655 (1993).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Massimino M et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med. Pediatr. Oncol.32, 32–37 (1999).
   PubMedGoogle Scholar
• Pappo AS, Fontanesi J, Luo X et al. Synovial sarcoma in children and adolescents: the St. Jude Children’s Research Hospital experience. J. Clin. Oncol.12, 2360–2366 (1994).
   PubMed Web of Science ®Google Scholar
• Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J. Clin. Oncol.21, 1602–1611 (2003).
   PubMed Web of Science ®Google Scholar
• Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol.15(11), 1667–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer101, 627–634 (2004).
   PubMed Web of Science ®Google Scholar
• Bergh P, Meis-Kindblom JM, Gherlinzoni F et al. Synovial sarcoma: identification of low and high risk groups. Cancer85, 2596–2607 (1999).
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Antonescu CR, Leung DHY et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J. Clin. Oncol.18, 2087–2094 (2000).
   PubMed Web of Science ®Google Scholar
• Spillane AJ, A’Hern R, Judson IR et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J. Clin. Oncol.18, 3794–3803 (2000).
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacène K et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J. Clin. Oncol.19, 525–534 (2001).
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr. Blood Cancer46, 11–17 (2006).
   PubMed Web of Science ®Google Scholar
• Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med.348(8), 694–701 (2003).
   PubMed Web of Science ®Google Scholar
• Raney RB, Asmar L, Newton WA Jr et al. Ewing’s sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J. Clin. Oncol.15(2), 574–582 (1997).
   PubMed Web of Science ®Google Scholar
• Castex MP, Rubie H, Stevens MC et al. Extraosseous localized ewing tumors: improved outcome with anthracyclines – the French society of pediatric oncology and international society of pediatric oncology. J. Clin. Oncol.25(10), 1176–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Kushner B H, La Quaglia M P, Wollner N et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J. Clin. Oncol.14, 1526–1531 (1996).
   PubMed Web of Science ®Google Scholar
• Brennan BMD, Foot ABM, Stiller C et al. Where to next with extracranial rhabdoid tumors in children. Eur. J. Cancer40, 624–626 (2004).
   PubMed Web of Science ®Google Scholar
• Loh ML, Ahn P, Perez-Atayde AR et al. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. Pediatr. Hematol. Oncol.24, 722–726 (2002).
   Web of Science ®Google Scholar
• Bollinger BK, Laskin WB, Knight CB. Epithelioid hemangioendothelioma with multiple site involvement. Literature review and observations. Cancer73, 610–615 (1994).
   PubMed Web of Science ®Google Scholar
• Fata F, O’Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer86, 2034–2037 (1999).
   PubMed Web of Science ®Google Scholar
• Penel N, Bui B, Bay JO et al. Weekly paclitaxel in metastatic angiosarocma. A FNCLCC French Sarcoma Group (GSF-GETO) Phase II trial. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10002).
   Google Scholar
• Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20, 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Maki R, Hensley ML, Wathen JK et al. A SARC multicenter Phase III study of gemcitabine vs. gemcitabine and docetaxel in patients with metastatic soft tissue sarcoma. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 9514).
   Google Scholar
• Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol.8(7), 595–602 (2007).
   PubMed Web of Science ®Google Scholar
• Morgan JA, Le Cesne A, Chawla S et al. Randomized Phase II study of trabectidine in patients with liposarcoma and leiomysarcoma after failure of prior anthracycline and ifosfamide. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10060).
   PubMed Web of Science ®Google Scholar
• Dileo P, Grosso F, Casanova M et al. Trabectidine in metastatic Ewing’s family tumors patients progressing after standard chemotherapy. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10040).
   Google Scholar
• Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer101(9), 2086–2097 (2004).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol.24(7), 1195–203 (2006).
   PubMed Web of Science ®Google Scholar
• McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol.23(4), 866–873 (2005).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Keohan M, Schuetze S et al. Clinical results of a Phase II study of sorafenib in patients with non GIST sarcomas (CTEP study 7060). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10001).
   Google Scholar
• Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue sarcomas: update of a Phase II trial. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10076).
   Google Scholar